Spider Venom Peptide Kills Brain Cancer Cells by Punching Holes in Their Membranes While Sparing Normal Cells | Research

The takeaway

A synthetic peptide derived from wolf spider venom killed 59% of glioblastoma cells via necroptosis within 3 hours by disrupting their membranes, while showing minimal toxicity to normal human cells.

59% necroptosis in 3 hours
Imaging flow cytometry confirmed that the spider venom peptide induced necroptosis — a regulated form of cell death — in the majority of glioblastoma cells within just 3 hours of treatment.

What the researchers found

LyeTxI-b, a cationic alpha-helical antimicrobial peptide, showed potent cytotoxicity against U87-MG glioblastoma cells through a membranolytic mechanism. Membrane disruption occurred within 15 minutes, confirmed by trypan blue uptake, reduced calcein-AM conversion, and LDH release. Scanning electron microscopy revealed physical holes and pores in the cancer cell membranes.

Imaging flow cytometry confirmed that 59% of cells underwent necroptosis after 3 hours of treatment. Necrostatin-1 (a necroptosis inhibitor) partially protected cells in a dose-dependent manner, confirming the necroptosis pathway. Transmission electron microscopy showed swollen nuclei, vacuolized organelles, and electron-lucent cytoplasm. Importantly, the peptide showed only mild cytotoxicity against normal human and monkey fibroblasts and low hemolytic activity.

Why it matters

Glioblastoma is nearly always fatal, and current treatments (surgery, radiation, temozolomide) extend survival by only months. The ability of LyeTxI-b to rapidly kill cancer cells through membrane disruption — a physical mechanism that bacteria and cancer cells can't easily develop resistance to — makes it an intriguing candidate. The selectivity for cancer cells over normal cells addresses one of the biggest challenges in anticancer peptide development.

How the study worked

The synthetic peptide LyeTxI-b was tested on U87-MG glioblastoma cells and normal fibroblast lines. Cell viability was assessed by multiple assays (trypan blue, calcein-AM, LDH release). Cell morphology was examined by scanning and transmission electron microscopy. Cell death pathways were characterized using imaging flow cytometry and the necroptosis inhibitor necrostatin-1. Hemolytic activity was tested on human red blood cells.

What this study cannot tell us

This was entirely an in vitro study on a single glioblastoma cell line (U87-MG). No animal tumor models were tested. The selectivity between cancer and normal cells, while encouraging, was observed in cell culture conditions that don't replicate the blood-brain barrier challenge of reaching brain tumors. Stability, pharmacokinetics, and immunogenicity of the peptide in vivo are unknown. The mechanism of cancer cell selectivity (likely related to membrane charge differences) was not fully elucidated.

How to read the evidence

This is a thorough in vitro mechanistic study with multiple complementary assays confirming the cell death mechanism. The evidence for the peptide's anticancer activity on this cell line is strong, but no in vivo or clinical data exist.

When this study was published

Published in 2019, this study is a few years old. Venom-derived anticancer peptides continue to be an active research area, with several groups now working on optimized analogs and delivery strategies for brain cancer.

The bigger picture

Venom-derived peptides are an increasingly important source of anticancer drug candidates. Spider, scorpion, and snake venoms have evolved to rapidly incapacitate prey through membrane disruption and ion channel modulation — mechanisms that can be redirected against cancer cells. The key advantage of membranolytic peptides is that resistance development is much harder than for drugs targeting specific proteins, because cancer cells would need to fundamentally change their membrane composition to escape.

Questions still open

Can LyeTxI-b cross the blood-brain barrier or be delivered to brain tumors via nanoparticle or other delivery systems?
Would the peptide show similar selectivity and efficacy against primary glioblastoma cells from patient tumors, which are more heterogeneous than cell lines?
Is the cancer cell selectivity driven by the higher negative charge of cancer cell membranes compared to normal cells?

Common questions

How does a spider venom peptide kill cancer cells?

LyeTxI-b is a positively charged helical peptide that is attracted to the negatively charged membranes of cancer cells. It inserts into the membrane and creates physical holes or pores, causing the cell contents to leak out. This triggers necroptosis, a form of programmed cell death. Normal cells have less negatively charged membranes, so the peptide is much less attracted to them.

Could this lead to a treatment for brain cancer?

It's a promising early finding, but significant challenges remain. The peptide would need to reach brain tumors, which means getting past the blood-brain barrier. It would also need to be tested in animal models to confirm it works in living organisms, not just in cell culture. If those hurdles can be cleared, it could become a candidate for further drug development.

Read the original research

The synthetic peptide LyeTxI-b derived from Lycosa erythrognatha spider venom is cytotoxic to U-87 MG glioblastoma cells.

Amino acids, 51(3), 433-449

View on PubMed ↗Publisher’s paper ↗

Citation

Abdel-Salam, Mostafa A L; Carvalho-Tavares, Juliana; Gomes, Kamila Sousa; Teixeira-Carvalho, Andrea; Kitten, Gregory T; Nyffeler, Johanna; Dias, Felipe F; Dos Reis, Pablo V Mendes; Pimenta, Adriano M C; Leist, Marcel; de Lima, Maria Elena; de Souza-Fagundes, Elaine Maria. (2019). The synthetic peptide LyeTxI-b derived from Lycosa erythrognatha spider venom is cytotoxic to U-87 MG glioblastoma cells.. Amino acids, 51(3), 433-449. https://doi.org/10.1007/s00726-018-2678-4